Literature DB >> 14695178

Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets.

Arturo Chavez-Reyes1, John M Parant, Lisa L Amelse, Roberto Montes de Oca Luna, Stanley J Korsmeyer, Guillermina Lozano.   

Abstract

The p53 tumor suppressor ensures maintenance of genome integrity by initiating either apoptosis or cell cycle arrest in response to DNA damage. Deletion of either mdm2 or mdm4 genes, which encode p53 inhibitors, results in embryonic lethality. The lethal phenotypes are rescued in the absence of p53, which indicates that increased activity of p53 is the cause of lethality in the mdm2- and mdm4-null embryos. Here we show that mdm2-null embryos die because of apoptosis initiated at 3.5 days postcoitum (dpc). Partial rescue of mdm2-null embryos by deletion of bax allows survival to 6.5 dpc and alters the mechanism of death from apoptosis to cell cycle arrest, indicating that bax is a critical component of the p53 pathway in early embryogenesis. The death of mdm4-null embryos is due to p53-initiated cell cycle arrest at 7.5 dpc. Deletion of p21(p21(waf1/cip1)), a p53 downstream target partially responsible for cell cycle arrest, does not rescue this phenotype; however, deletion of p21 alters the mechanism of cell death from lack of proliferation to apoptosis. Thus, in both examples, deletion of a p53 downstream target gene allows p53 to redirect its efforts, highlighting a high degree of plasticity in p53 function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695178

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

Review 1.  Making sense of ubiquitin ligases that regulate p53.

Authors:  Abhinav K Jain; Michelle Craig Barton
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

2.  Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching.

Authors:  Sylvia Hilliard; Karam Aboudehen; Xiao Yao; Samir S El-Dahr
Journal:  Dev Biol       Date:  2011-03-21       Impact factor: 3.582

3.  Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.

Authors:  Shunbin Xiong; Carolyn S Van Pelt; Ana C Elizondo-Fraire; Geng Liu; Guillermina Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

4.  HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  Genglin Jin; Stephen Cook; Bo Cui; William C Chen; Stephen T Keir; Patrick Killela; Chunhui Di; Cathy A Payne; Simon G Gregory; Roger McLendon; Darell D Bigner; Hai Yan
Journal:  Neuro Oncol       Date:  2010-05-14       Impact factor: 12.300

5.  Cryopreservation: An emerging paradigm change.

Authors:  John G Baust; Dayong Gao; John M Baust
Journal:  Organogenesis       Date:  2009-07       Impact factor: 2.500

Review 6.  The regulation of the p53-mediated stress response by MDM2 and MDM4.

Authors:  Mary Ellen Perry
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

7.  Guilty as CHARGED: p53's expanding role in disease.

Authors:  Jeanine L Van Nostrand; Laura D Attardi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Mdm2 and Mdm4 loss regulates distinct p53 activities.

Authors:  Juan A Barboza; Tomoo Iwakuma; Tamara Terzian; Adel K El-Naggar; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

9.  Daxx Functions Are p53-Independent In Vivo.

Authors:  Amanda R Wasylishen; Jeannelyn S Estrella; Vinod Pant; Gilda P Chau; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2018-06-14       Impact factor: 5.852

10.  Identification of retinoic acid-regulated nuclear matrix-associated protein as a novel regulator of gastric cancer.

Authors:  J Li; E K O Ng; Y P Ng; C Y P Wong; J Yu; H Jin; V Y Y Cheng; M Y Y Go; P K F Cheung; M P A Ebert; J Tong; K F To; F K L Chan; J J Y Sung; N Y Ip; W K Leung
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.